54903-16-1

Basic information

• Product Name: 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid
• Synonyms: 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid;6-Benzoxazolecarboxylic acid, 2,3-dihydro-2-oxo-;2-oxobenzoxazole-6-carboxylic acid
• CAS NO: 54903-16-1
• Molecular Formula: C₈H₅NO₄
• Molecular Weight: 179.13
• EINECS: 604-604-1
• Mol File: 54903-16-1.mol

Chemical Properties

• Melting Point: >340°
• Appearance: /
• Density: 1.563 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.01±0.20(Predicted)
• CAS DataBase Reference: 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid(54903-16-1)
• EPA Substance Registry System: 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid(54903-16-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 54903-16-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications. Its unique structure allows for the creation of diverse molecular entities that can target various biological pathways.
Used in Agrochemical Development:
In the agrochemical industry, 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid is utilized as a building block in the synthesis of new agrochemicals, such as pesticides and herbicides, due to its potential to enhance the effectiveness and selectivity of these compounds in agricultural applications.
Used in Research and Development of New Chemical Entities:
2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid serves as a versatile intermediate in the research and development of new chemical entities, facilitating the exploration of novel chemical space and the discovery of compounds with unique properties and applications across various industries.
Used in Organic Synthesis:
As a heterocyclic compound, 2-Oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylic acid is used in organic synthesis to produce a wide range of heterocyclic compounds. Its presence in the synthesis process allows for the creation of complex molecular structures that can be applied in various chemical reactions and processes, contributing to the advancement of the chemical industry.

Upstream product

• 2374-03-0 4-aminosalicylic acid 
• 79-22-1 methyl chloroformate 
• 59-49-4 2-Benzoxazolinone 
• 54903-09-2 6-acetyl-3H-benzooxazol-2-one 
• 207552-92-9 6-Ethoxycarbonylbenzoxazolin-2-one 
• 72752-80-8 methyl 2-oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylate 
• 861312-43-8 4-ethoxycarbonylamino-3-hydroxy-benzoic acid 

Downstream Products

• 1248727-79-8 6-(4-{4-[3-(4-trifluoromethyl-phenyl)-propionyl]-piperazin-1-yl}-piperidine-1-carbonyl)-3H-benzooxazol-2-one 
• 1121767-06-3 C₂₀H₂₁ClN₄O₃ 
• 924300-28-7 C₁₆H₁₁NO₅ 

Relevant articles and documents

Compound with dopamine D3 receptor adjusting activity, and applications thereof

The invention relates to a compound with dopamine D3 receptor adjusting activity, and applications thereof, and more specifically discloses dopamine receptor D3R as a novel target of post-traumatic stress disorder (PTSD) in prevention, treatment/or auxiliary treatment of PTSD, and screening of anti-PTSD medicines, and relates to applications of a compound with dopamine receptor D3R adjusting activity in preparation of medicines used for preventing, treatment and/or auxiliary treatment of PTSD.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

Synthesis of some novel benzoxazolinonylcarboxamides as potential anti-inflammatory agents

The synthesis of new 2(3H )-benzoxazolinonylcarboxamides starting from 2-amino-4,6-dimethylpyridine and 2(3H )-benzoxazolone which were designed as anti-inflammatory agents is described. These derivatives were synthesised from 2(3H )-(benzoxazolinon-6-yl)carboxylic acids, which were obtained by Friedel-Crafts acylation of 2(3H )-benzoxazolone derivatives with oxalyl chloride and acetylchloride in the presence of the AlCl3-DMF complex. The constitution of the products was supported by elemental analysis IR and 1H NMR spectral data.

NOVEL DOPAMINE D3 RECEPTOR LIGANDS, THE PREPARATION AND USE THEREOF

The invention discloses novel piperazine derivatives represented by formula I having activity for modulating dopamine D3 receptor, their stereoisomers, pharmaceutical salts, solvates, and the pharmaceutical compositions containing such compounds, their preparation and the use of such compounds for preventing or treating the diseases correlated with central nervous system disorder, such as Parkinson's disease, schizophrenia, drug addiction and relapse and the like, as well as the use of such compounds for kidney protection and immune modulation, or as implemental medicine for researching the function of D3R and the diseases correlated with disorder of D3R function.

NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME

The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson''s disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.

THIADIAZOLE MODULATORS OF PKB

The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the th

BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds which are derivatives of benzamide and suitable in methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions .

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists

Described are piperidines of Formula I and pharmaceutically acceptable salts thereof. The compounds of Formula I are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.